XOMA Corporation (XOMA) Disappoints

XOMA Corporation (XOMA) shares are down $0.04 to $3.68 in after-hours trading Wednesday after the company reported its fourth quarter 2014 earnings results.

The drug developer reported earnings of ($0.12) per share on revenues of $4.3 million, down 65.6% from a year ago. Analysts were expecting EPS of ($0.09) on revenues of $11.17 million.

For the year ended Dec. 31, 2014, the company reported that its loss narrowed to $38.3 million from $124.1 million in 2013. Revenue was reported as $18.9 million, compared with $35.5 million in 213.

On valuation measures, XOMA Corp. shares, which currently have an average 3-month trading volume of 2.58 million shares, trade at a P/E to growth ratio of (0.4). The median Wall Street price target on the name is $9.00 with a high target of $17.00. Currently ticker boasts 7 ‘Buy’ endorsements, compared to 2 ’Holds’ and no ‘Sell’.

Profitability-wise, XOMA has a t-12 operating margin of (288.63%). The $399.51 million market cap company reported $78.4 million in cash in its most recent quarter.

XOMA currently prints a one year loss of 36.63% and a year-to-date return of 3.62%.

The chart below shows where the equity has traded over the last 52 weeks.

XOMA Corp. discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company was founded in 1981 and is headquartered in Berkeley, California.

Create Content With AI

Try TradingView For Free

Risk Our Money Not Yours | Get 50% Off Any Account

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.